AVANIR Announces Last Patient Enrolled in Neuropathic Pain Phase III Trial with Zenvia
16th Nov 2006, 09:40 GMT
AVANIR Pharmaceuticals announced that the Company has enrolled the targeted number of patients needed to assess the efficacy endpoint in its ongoing Zenvia Phase III painful diabetic neuropathy trial.
Latest news from Nephrology/ Dialysis News from StratCenter.com:
- New Data Show ACTOS Halted Progression of Atherosclerosis as Indicated by CIMT in Patients with Type 2 Diabetes
- Ruboxistaurin Reduced Vision Loss in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy in a New Study
- Aksys Reports Q3 2006 Financial Results
- Altus Pharmaceuticals Announces Presentation of ALTU-238 Phase II Data at Int'l Congress of Growth Hormone and Insulin-Like Growth Factor Research Societies
- Opexa Reports Q3 Financial Results
- Treatment of Diabetic Foot Ulcers Addressed at Upcoming American Heart Assoc Meeting
- Weight Loss Surgery Assists in Eliminating, Avoiding Type 2 Diabetes; American Institute of Gastric Banding Recognizes November as Nat'l Diabetes Month
- Federal Economic Development Agency Enlists Support of African-American Churches in the IL Delta
- Federal Economic Development Agency Enlists Support of African-American Churches in the MS Delta
- Federal Economic Development Agency Enlists Support of African-American Churches in the LA Delta